内部人交易

EDGAR

Evoke Pharma Inc

董事、高级管理人员和10%以上股东在SEC表格3、4、5中报告的交易,读取自每份申报文件的XML。代码及其措辞均为SEC原文。

表格4须在交易后两个工作日内提交,因此最近的交易可能尚未申报。

范围:日期在2025年11月16日或之后的交易。

公开市场买入(代码P)
0笔交易,—股
公开市场卖出(代码S)
0笔交易,—股

合计为所列已申报交易之和;它们统计的是已报告的内容,并不表示方向。

显示第1–37项,共37项

内部人交易,最新在前,按SEC表格3、4、5所申报
日期报告人代码取得或处置股数每股价格(按申报)价值(推算)交易后持股直接或间接规则10b5-1勾选框脚注来源
2025年12月17日 申报日期:2025年12月19日Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
处置(D)148,15311.00
1,629,683

推算:股数 × 每股价格。精确值 1629683.00。

0间接(I) See Footnote否
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
打开申报文件 0001104659-25-123156 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月19日Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

衍生证券: Prefunded Warrants — 标的 Common Stock (433,962) — 行权价 0.0001
处置(D)433,96210.999
4,773,148.038

推算:股数 × 每股价格。精确值 4773148.038。

0间接(I) See Footnote否
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
打开申报文件 0001104659-25-123156 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月19日Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

衍生证券: Series A Common Stock Purchase Warrants — 标的 Common Stock (117,019) — 行权价 8.16
处置(D)117,0194.71
551,159.49

推算:股数 × 每股价格。精确值 551159.49。

0间接(I) See Footnote否
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
打开申报文件 0001104659-25-123156 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月19日Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

衍生证券: Series C Common Stock Purchase Warrants — 标的 Common Stock (117,019) — 行权价 8.16
处置(D)117,0194.71
551,159.49

推算:股数 × 每股价格。精确值 551159.49。

0间接(I) See Footnote否
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
打开申报文件 0001104659-25-123156 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月19日Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

衍生证券: Amended Series A Common Stock Purchase Warrants — 标的 Common Stock (158,531) — 行权价 0.01
处置(D)158,53110.99
1,742,255.69

推算:股数 × 每股价格。精确值 1742255.69。

0间接(I) See Footnote否
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
打开申报文件 0001104659-25-123156 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月19日Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

衍生证券: Amended Series C Common Stock Purchase Warrants — 标的 Common Stock (250,627) — 行权价 0.01
处置(D)250,62710.99
2,754,390.73

推算:股数 × 每股价格。精确值 2754390.73。

0间接(I) See Footnote否
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
打开申报文件 0001104659-25-123156 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,218) — 行权价 5.41
处置(D)1,218——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322642 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (5,833) — 行权价 4.45
处置(D)5,833——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322642 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,218) — 行权价 3.453
处置(D)1,218——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322642 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,479) — 行权价 5.41
处置(D)1,479——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322643 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (8,750) — 行权价 4.45
处置(D)8,750——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322643 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,291) — 行权价 3.453
处置(D)1,291——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322643 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,187) — 行权价 5.41
处置(D)1,187——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322641 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (5,833) — 行权价 4.45
处置(D)5,833——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322641 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,187) — 行权价 3.453
处置(D)1,187——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322641 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,250) — 行权价 5.41
处置(D)1,250——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322638 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (5,833) — 行权价 4.45
处置(D)5,833——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322638 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,250) — 行权价 3.453
处置(D)1,250——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322638 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,218) — 行权价 5.41
处置(D)1,218——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322639 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (5,833) — 行权价 4.45
处置(D)5,833——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322639 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,187) — 行权价 3.453
处置(D)1,187——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322639 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (5,833) — 行权价 5.51
处置(D)5,833——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322645 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,125) — 行权价 3.453
处置(D)1,125——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322645 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (17,291) — 行权价 5.27
处置(D)17,291——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322644 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (11,000) — 行权价 4.45
处置(D)11,000——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322644 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (64,840) — 行权价 5.27
处置(D)64,840——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322637 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (70,000) — 行权价 4.45
处置(D)70,000——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322637 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (17,291) — 行权价 5.27
处置(D)17,291——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322640 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (13,000) — 行权价 4.45
处置(D)13,000——0直接(D) 否
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322640 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (5,833) — 行权价 5.26
处置(D)5,833——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322646 读取自申报文件的XML 对此行提出异议
2025年12月17日 申报日期:2025年12月17日PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

衍生证券: Stock Option (Right to Buy) — 标的 Common Stock (1,155) — 行权价 3.453
处置(D)1,155——0直接(D) 否
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
打开申报文件 0001193125-25-322646 读取自申报文件的XML 对此行提出异议
2025年12月16日 申报日期:2025年12月17日Hill Malcolm R Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
处置(D)133——0直接(D) 否
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
打开申报文件 0001193125-25-322642 读取自申报文件的XML 对此行提出异议
2025年12月16日 申报日期:2025年12月17日GARNER CAM L Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
处置(D)2,330——0间接(I) By Garner Investments, L.L.C.否
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
打开申报文件 0001193125-25-322643 读取自申报文件的XML 对此行提出异议
2025年12月16日 申报日期:2025年12月17日Brady Todd C Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
处置(D)27——0直接(D) 否
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
打开申报文件 0001193125-25-322639 读取自申报文件的XML 对此行提出异议
2025年12月16日 申报日期:2025年12月17日CARLSON MARILYN R. Officer: Chief Medical Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
处置(D)360——0直接(D) 否
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
打开申报文件 0001193125-25-322644 读取自申报文件的XML 对此行提出异议
2025年12月16日 申报日期:2025年12月17日D'Onofrio Matthew J Director · Officer: Chief Executive Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
处置(D)15,509——0直接(D) 否
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
打开申报文件 0001193125-25-322637 读取自申报文件的XML 对此行提出异议
2025年12月16日 申报日期:2025年12月17日Kowieski Mark Officer: Chief Financial Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
处置(D)11,815——0直接(D) 否
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
打开申报文件 0001193125-25-322640 读取自申报文件的XML 对此行提出异议

机构持有人(表格13F)

库中没有归属于该发行人的表格13F持仓。尚未关联或尚未申报的持有人是缺失,而不是零。

5%持有人(附表13D和13G)

此处读取SEC结构化格式(2024年末起)提交的附表。更早的附表是自由文本,不予读取。

5%持有人,最新事件在前,按申报
持有人占该类别比例持股数事件日期表格来源
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share00.0012/17/2025 申报日期:2025年12月19日SCHEDULE 13D/A第5号修订打开申报文件 0001104659-25-123157 对此行提出异议
Harkey Wilmot B. Common Stock, par value $0.0001 per share00.0012/17/2025 申报日期:2025年12月19日SCHEDULE 13D/A第5号修订打开申报文件 0001104659-25-123157 对此行提出异议
Mack Daniel Common Stock, par value $0.0001 per share00.0012/17/2025 申报日期:2025年12月19日SCHEDULE 13D/A第5号修订打开申报文件 0001104659-25-123157 对此行提出异议
Morgan Stanley Common Stock0.03111/30/2025 申报日期:2025年12月5日SCHEDULE 13G/A第1号修订打开申报文件 0000895421-25-000595 对此行提出异议
Morgan Stanley Smith Barney LLC Common Stock0.03111/30/2025 申报日期:2025年12月5日SCHEDULE 13G/A第1号修订打开申报文件 0000895421-25-000595 对此行提出异议
Klein Roger M. Common Stock, par value $0.0001 per share10.5163,000.0011/04/2025 申报日期:2025年11月12日SCHEDULE 13D打开申报文件 0001651175-25-000007 对此行提出异议
Krieger Charitable Trust Common Stock, par value $0.0001 per share8.3129,000.0011/04/2025 申报日期:2025年11月12日SCHEDULE 13D打开申报文件 0001651175-25-000007 对此行提出异议
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 申报日期:2025年11月4日SCHEDULE 13D/A第4号修订打开申报文件 0001104659-25-106048 对此行提出异议
Harkey Wilmot B. Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 申报日期:2025年11月4日SCHEDULE 13D/A第4号修订打开申报文件 0001104659-25-106048 对此行提出异议
Mack Daniel Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 申报日期:2025年11月4日SCHEDULE 13D/A第4号修订打开申报文件 0001104659-25-106048 对此行提出异议
Morgan Stanley Common Stock10.5163,71808/31/2025 申报日期:2025年9月8日SCHEDULE 13G打开申报文件 0000895421-25-000528 对此行提出异议
Morgan Stanley Smith Barney LLC Common Stock10.5163,71808/31/2025 申报日期:2025年9月8日SCHEDULE 13G打开申报文件 0000895421-25-000528 对此行提出异议

比例是申报文件所指类别的比例,由持有人自行陈述。团体成员各自报告团体的股份,因此各行不应相加。

已读取的内容

已读取2,093,437份申报文件,日期为2004年6月14日至2026年11月13日:表格3, 3/A, 4, 4/A, 5, 5/A。

档案仍在读取时,某些年份可能不完整。某年在此显示的申报较少,并不表示实际提交得少。

按申报年份统计已读取的文件
申报年份已读取文件
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024186,415
2025235,520
2026254,737

SEC要求使用XML之前提交的文件只列出,不提取内容。

返回Evoke Pharma Inc